Psoriatic arthritis patients treated with etanercept had reductions in healthcare resource utilization—Results from the experience diagnosing, understanding care, and treatment with enbrel (educate) trial - 21/08/11
J. Mark Jackson, MD, Dermatology Specialists, PSC, Louisville, KY, United States; Erin Boh, MD, Tulane Medical School, New Orleans, LA, United States; Drore Eisen, MD, private practice, Cincinnati, OH, United States; Amy H. Xia, PhD, Amgen Inc., Thousand Oaks, CA, United States
Le texte complet de cet article est disponible en PDF. P2781 Dr. Jackson has performed research or received consulting, honoraria and/or support from the following companies: 3M Pharmaceuticals, Amgen, Biogen, Collagenix, Connetics, Ferndale, Galderma, Genentech, Medicis, Novartis, and Roche. Dr. Erin Boh has no financial interests in any biologic manufactures and is a member of the speakers bureau for the following companies: Amgen, Biogen, and Genentech. Research funded by Immunex Corporation, a wholly owned subsidiary of Amgen Inc., and by Wyeth Research |
Vol 52 - N° 3S
P. P192 - mars 2005 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?